Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial

Published:2014 Issue:1 Volume:132 Page:87-96
ISSN:0001-5792
Container-title:Acta Haematologica
language:en
Short-container-title:Acta Haematol

Author:

Kim Hawk,Lee Je-Hwan,Joo Young-Don,Bae Sung Hwa,Lee Jung-Hee,Kim Dae-Young,Lee Won-Sik,Ryoo Hun-Mo,Jo Jae-Cheol,Park Jae-Hoo,Lee Kyoo-Hyung,

Publisher

S. Karger AG

Subject

Hematology,General Medicine

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia;Hematology;2023-10-05

2. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia;Leukemia & Lymphoma;2018-10-02

3. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

4. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial;European Journal of Haematology;2015-05-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP